Regeneron beats Q2 estimates as Dupixent hits record $6B quarter

Plus: Wellstar Health System cuts 761 corporate jobs. The day's rules, money, and enforcement, sourced and tiered below.

Share

Plus: Wellstar Health System cuts 761 corporate jobs. The day's rules, money, and enforcement, sourced and tiered below.

American Health Intel
Rules · Money · Medicine · Decoded daily
The Ledger Sunday, August 2, 2026
Regeneron beats Q2 estimates as Dupixent hits record $6B quarter
Plus: Wellstar Health System cuts 761 corporate jobs. The day's rules, money, and enforcement, sourced and tiered below.
Earnings  Confidence: High
Regeneron, the biotech behind blockbuster eczema and asthma drug Dupixent, beat Wall Street's second-quarter estimates on both revenue and profit, as Dupixent posted its biggest quarter ever.
Revenue hit $4.29 billion, up 17%. Dupixent's global sales jumped 38% to $6.0 billion, a record, while Regeneron's own EYLEA HD and Libtayo each grew more than 30% and also hit new sales highs.
Why it matters
Regeneron's blowout quarter shows demand for its immunology and eye drugs keeps climbing, a sign biotech innovation is still commanding premium pricing. Watch whether Dupixent's growth holds as competitors enter the eczema and asthma space.
Sources: Globenewswire · SEC
Other  Confidence: High
Wellstar Health System, the nonprofit hospital network that is one of Georgia's largest employers, is cutting 761 corporate and administrative jobs, about 2% of its workforce.
The cuts hit corporate and shared-services functions and some administrative roles, not frontline caregivers. Wellstar says the move follows an industry-benchmark review meant to simplify its structure and speed decision-making.
Why it matters
A major nonprofit hospital system trimming corporate staff signals financial pressure even at large, established health systems. Watch whether other Georgia or regional systems follow with similar restructuring.
Also today
Guardian Dentistry Partners acquires 38-location Select Dental Management Read
FRONTIER SCAN: Knox Lane's $437M Cross Country Healthcare buyout Read
364
Records
$28.6B
Enforcement
17
Deadlines
108
Rules
Read this issue + the trackers
Pick your field on the site and every story tells you what it means for you.
Reply to this email and tell us what you want covered. We read everything.
We show our work. We score our own calls.
News and analysis, not legal, medical, coding, or investment advice.
You subscribed at americanhealthintel.com · Unsubscribe